首页/数据集/Dataset from A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis

Dataset from A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis

NIAID Data Ecosystem2026-05-02 收录

银屑病药物临床试验

抗IL-17抗体疗效评估

数据链接：

https://doi.org/10.25934/00004480 数据链接链接失效反馈

官方服务：

资源简介：

The primary purpose for this study is to help answer the following research questions - The safety of ixekizumab (LY2439821) and any side effects that might be associated with it. - Whether ixekizumab can help participants with Psoriasis. - How much ixekizumab should be given to participants.

应用场景：

创建时间：

2025-02-22

银屑病药物临床试验

代谢综合征亚组分析

Supplemental material for Lebwohl, et al., "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two

NIAID Data Ecosystem70

Supplementary Materials for: Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2 trial

银屑病药物临床试验

TYK2抑制剂研究

This dataset contains supplementary materials for the following publication: Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2

NIAID Data Ecosystem10

Supplementary Data for: Highly selective, allosteric inhibition of TYK2 with oral ESK 001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

银屑病药物临床试验

TYK2

This dataset contains supplementary data for the following publication: Highly selective, allosteric inhibition of TYK2 with oral ESK 001 in patients with moderate-to-severe plaque psoriasis: Results

Mendeley Data00

Supplemental material for JAAD publication titled: Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study

银屑病药物临床试验

儿科皮肤病

Supplemental material for JAAD publication titled: "A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe p

Mendeley Data10

银屑病药物临床试验

儿科皮肤病

Supplemental material for JAAD publication titled: "Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a P

Mendeley Data2020-11-12 更新10

Dataset from A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis

资源简介：

相关数据集